Dr. Jeffrey Fu, CBO, Codagenix, describes what is needed in next-generation COVID vaccines.
Our vaccine program strives address these factors as a live-attenuated, intranasal vaccine that induces an antibody and cell-mediated immunity (CMI).
Learn more: https://t.co/MsnloriRwg
Did you know? RSV poses a significant risk to children; more than half of RSV deaths occur in children ages 6 months and older.
Learn more about our work to develop an RSV vaccine for children: https://t.co/MsnloriRwg
At Codagenix, we're combining cutting-edge AI and #syntheticbiology to create safer, more effective live-attenuated #virus#vaccines. ️
Learn more: https://t.co/3Ju3xhIEEJ
Today, on International Day of Women and Girls in Science, we shine a spotlight on the incredible #womeninscience who push the boundaries of science and healthcare, including our very own Director of Preclinical Operations, Keri Wyllie, MPA.
Learn more: https://t.co/EeTDllxqz3
#ICYMI – Check this article from @ritarubin on @JAMA_current highlighting Codagenix's work on next-gen #vaccines, incl. those targeting the mucosal immune system via the nose, mimicking the natural infection route.
Read the full article: https://t.co/R0nLwAx8P6
Curious to learn about the biggest takeaways from #JPM24? Check out this article from @BioSpace that includes updates from Codagenix and many more.
Read here: https://t.co/RZXpC57RnB
#biopharma#biotech#innovation#healthcare
Codagenix CEO, Paul Grint, MD, was interviewed for this @WSJVC feature by Brian Gormley about the recent uptick in #biotech acquisitions.
Read here: https://t.co/CsQHMxFuXF
#biopharma#innovation#healthcare
#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D.
Read the full article: https://t.co/NvXThQZbz4
Check out this article from @cwillyard in @techreview about the future of needle-free COVID #vaccines, and how Codagenix is among the companies leading the way.
https://t.co/7ooxFM6FbJ
Thank you @ritarubin and @JAMA_current for highlighting Codagenix's work on next-gen #vaccines, including those targeting the mucosal immune system via the nose, mimicking the natural route of the virus.
Read the full article: https://t.co/R0nLwAwAZy
This #JPM24, Codagenix’s CEO Paul Grint had the opportunity to speak with Tyler Patchen of @BioSpace about Codagenix’s live attenuated virus approach to #vaccine development.
Read the full article: https://t.co/GHIEFMnr4x
Team Codagenix is attending the 2024 JPMorgan Healthcare Conference in San Francisco, January 8-11. Contact us to schedule a meeting.
Learn more about our work: https://t.co/MsnloriRwg
#JPM2024#JPM24
Dr. Johanna Kaufmann, EVP Oncology and Immunology, will be participating in a panel at the 8th Annual Oncolytic Virotherapy Summit on December 14 at noon ET. We hope to see you there!
Learn more: https://t.co/h4soAzb5cJ
#DYK that virotherapies have the potential to modulate the tumor microenvironment and trigger immune mechanisms to fight #cancer? At Codagenix, we explore novel #virotherapeutics for #breastcancer and other solid tumors.
Learn more about our pipeline: https://t.co/eT0VzlsWMB
Thank you @BioWorld for highlighting Codagenix’s @DeptofDefense award of $5.88 million to advance its tetravalent #dengue#vaccine program.
Learn more: https://t.co/EK5PyxK3hw
#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D.
Read the full article: https://t.co/NvXThQZbz4
This Thanksgiving, we are #grateful for the incredible team of scientists and researchers at Codagenix who are dedicated to taking on the biggest threats in #infectiousdiseases and #cancer through our powerful codon-modification platform.
Dr. Johanna Kaufmann, EVP Oncology and Immunology, recently spoke to @sabrinaserani of @TargetedOnc about Codagenix’s #oncolytic#virotherapy platform.
Watch the full interview: https://t.co/ef1nmGSXq8
Today Codagenix announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for #breastcancer#immunovirotherapy, at the @sitcancer 38th Annual Meeting taking place November 1-5, 2023, in San Diego, California.
https://t.co/3Hoj01qjh2